Navigation Links
Cylex Announces Brad L. Stewart as President of the Company

Mr. Stewart brings critical experience in strategic and operational

leadership to support expansion of the Company's current and future


COLUMBIA, Md., April 8, 2008 /PRNewswire/ -- Cylex(TM) has announced the appointment of Brad L. Stewart as President of the Company. Cylex is a global life sciences company that develops and manufactures research and in vitro diagnostic products based on its patented technology to assay cell-mediated immunity (CMI).

(Photo: )

"A major priority for Cylex has been the recruitment of an experienced leader who could bring greater focus to the company and convert our extraordinary patented technology assets into profitable product opportunities," said Seth Rudnick, MD, General Partner in Canaan VII (a Canaan Partners fund), a major investor in Cylex, in announcing Mr. Stewart's appointment. "We believe Brad is the individual who brings us that skill set."

"I am delighted to have been given this opportunity to join Cylex and to focus first and foremost on ways to expand the awareness of our first marketed product, the ImmuKnow(R) assay, within and beyond the transplant community," says Mr. Stewart. "I have already had the chance to identify means to accelerate understanding of the value of this technology in specific therapeutic areas. We are also convinced that Cylex can rapidly expand ex-US use of ImmuKnow to support patient care in many other countries. This is an exciting challenge for me personally, and I will have the backing of a talented team of professionals at Cylex who, I know, are eager to work with me in achieving very specific goals."

Mr. Stewart brings extensive leadership experience in the life sciences industry -- with biotech, pharmaceutical, orphan drug, diagnostic and related healthcare companies. Among other accomplishments, he established a new US business for a European pharmaceutical company; drove the strategic restructuring of the North American business unit of a global pharmaceutical company; created an operational improvement business within a major diagnostics company; and developed and managed joint ventures, including a multi-million dollar joint-venture with one of the world's largest pharmaceutical companies.

At Cylex, he will have full responsibility for global commercial operations, corporate strategy and business development.

About Cylex(TM) Inc.

Cylex(TM) is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow(R) is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the US and abroad. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The Company is based in Columbia, MD.

SOURCE Cylex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
2. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
3. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
4. Martek Announces Final Judgment and Order of Dismissal in Class Action
5. Microbia Announces Name Change to Ironwood Pharmaceuticals
6. China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier
7. Medicsight Announces New Marketing Partnership with INFINITT
8. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
9. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
10. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
11. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
Post Your Comments:
(Date:11/28/2015)... South Korea (PRWEB) , ... November 28, 2015 , ... ... class of eco-friendly avian, porcine and rodent control solutions , ... as peppermint and cinnamon oil, works across all sensory modalities including visual, smell, taste ...
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
(Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
Breaking Biology News(10 mins):